View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 9, 2022

YPrime acquires Tryl to bolster expertise for decentralised trials

The tools of Tryl offer a tailored and predictive experience to the complete patient journey.

YPrime has acquired software development company Tryl to expand its expertise to support decentralised clinical trials.

Tryl’s patient engagement solution combines personalisation and applied behavioural science to increase engagement, cut down dropouts, and provide results in clinical trials. 

With the Tryl takeover, YPrime will gain access to all the development expertise, staff and intellectual properties and will merge with Patient Engagement Technologies solutions of the latter.

The tools of Tryl offer a tailored, predictive and relative experience to the complete journey of the patient. 

Furthermore, its engagement score could lower the rate of patient dropouts

YPrime CEO Shawn Blackburn said: “YPrime’s major priority has always been to anticipate the needs of tomorrow’s clinical trials and create powerful eClinical tools that simplify the lives of sponsors, sites, and patients. 

“This combination with Tryl helps us leap ahead in fulfilling our vision of creating the industry’s first-of-its-kind solution to help keep patients more informed and engaged throughout the entire clinical trial process, especially as our industry accelerates toward decentralised clinical trial models.”

The Tryl team uses established behavioural principles from other industries such as professional sports and consumer finance to boost patient adherence to trial protocols.

Its predictive analytics aid clinicians to intervene before the dropout of the study subjects. This method lowers the burden of participants while also increasing value for sponsors as well as researchers.

Tryl CEO Ian Greenfield said: “An ever-increasing focus on patient centricity demands an integrated approach to how patients are engaged. 

“YPrime has a strong vision for the future and by bringing together offerings from our two companies, we can create a novel solution that takes head on the most pressing challenges associated with attracting, engaging, and retaining patients.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU